New COVID-19 vaccine trial includes children as young as 3
NCT ID NCT04869592
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new recombinant COVID-19 vaccine (made using CHO cells) in healthy people aged 3 and older. The trial involved 3,100 participants across two phases to check safety, side effects, and immune response. Participants received either a low or high dose of the vaccine or a placebo, with three shots given over 60 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant SARS-CoV-2 vaccine (CHO cell)
- What this could lead to
- If successful, this could provide a safe and effective COVID-19 vaccine option for people as young as 3 years old.
- What could go wrong
- This is an early-phase trial focused on safety and immune response, not yet proven to prevent COVID-19. Results may not apply to newer virus variants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?